Table 3:
Competing risk analysis for the effect of INR on risk of hemorrhage among patients with chronic liver disease and warfarin users
| Parameter | Adjusted Hazard Ratio of Hemorrhage (95% Confidence Interval) |
|
|---|---|---|
| Chronic Liver Disease | Warfarin users | |
|
| ||
| Age* per decade | 0.88 (0.79–0.98) | 1.12 (1.05–1.19) |
|
| ||
| Gender* (Female versus Male) | 1.45 (0.93–2.28) | 0.53 (0.28–0.98) |
|
| ||
| HTN* | 1.00 (0.83–1.21) | 1.40 (1.16–1.69) |
|
| ||
| International Normalized Ratio* | ||
| ≤1.50 | Referent | Referent |
| 1.50–2.0 | 2.25 (1.77–2.85) | 0.86 (0.71–1.05) |
| >2.0–2.5 | 1.80 (1.11–2.91) | 0.81 (0.67–0.98) |
| >2.5–3.0 | 1.60 (0.74–3.45) | 1.18 (0.97–1.44) |
| >3.0–3.5 | 1.74 (0.421–7.23) | 1.64 (1.29–2.08) |
| >3.5 | 2.47 (0.89–6.82) | 4.70 (3.94–5.60) |
|
| ||
| Platelet count* <50 × 109/L | 1.06 (0.71–1.59) | 3.07 (1.15–8.22) |
|
| ||
| Alcohol Use | 1.40 (1.19–1.65) | |
|
| ||
| Anemia | 1.56 (1.40–1.73) | |
|
| ||
| Anti-platelet therapy | 1.59 (1.41–1.79) | |
|
| ||
| Cardiovascular disease | 1.17 (1.05–1.31) | |
|
| ||
| Chronic Kidney Disease | 2.10 (1.83–2.42) | |
|
| ||
| Chronic Lung disease | 1.25 (1.13–1.39) | |
|
| ||
| Dementia | 1.25 (0.91–1.72) | |
|
| ||
| Fracture | 2.38 (1.33–4.28) | |
|
| ||
| Hemi or paraplegia | 1.57 (1.09–2.26) | |
|
| ||
| Peptic Ulcer disease | 1.37 (1.08–1.74) | |
|
| ||
| Surgery | 5.22 (4.20–6.49) | |
|
| ||
| Trauma | 3.08 (2.50–3.80) | |
|
| ||
*
indicates interaction term results; Abbreviations: HTN= hypertension, INR= International Normalized Ratio, aHR= adjusted hazards ratio